Processa Pharmaceuticals Stock Down 4.1 %
PCSA opened at $0.39 on Thursday. Processa Pharmaceuticals has a 52 week low of $0.18 and a 52 week high of $2.24. The business has a 50 day moving average price of $0.33 and a two-hundred day moving average price of $0.45. The company has a market cap of $9.70 million, a PE ratio of -0.34 and a beta of 0.11.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new stake in shares of Processa Pharmaceuticals during the second quarter worth approximately $33,000. Dimensional Fund Advisors LP acquired a new stake in shares of Processa Pharmaceuticals in the 3rd quarter worth $28,000. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Processa Pharmaceuticals in the fourth quarter valued at about $54,000. Two Sigma Securities LLC purchased a new position in Processa Pharmaceuticals during the first quarter worth about $31,000. Finally, Citadel Advisors LLC acquired a new stake in Processa Pharmaceuticals in the second quarter valued at about $141,000. 5.67% of the stock is currently owned by hedge funds and other institutional investors.
Processa Pharmaceuticals Company Profile
Processa Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.
- Five stocks we like better than Processa Pharmaceuticals
- How to Use the MarketBeat Stock Screener
- Unlocking AI investment opportunities in healthcare
- Airline Stocks – Top Airline Stocks to Buy Now
- New Disney investor propels stock to ranks of best S&P gainers
- What to Know About Investing in Penny Stocks
- Buffett’s latest portfolio additions, trims, and cuts in Q3
Receive News & Ratings for Processa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Processa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.